tbuckley/cabot-search huggingface dataset:
Elevation of Kinase Interacting with Stathmin (KIS) and Promotion of Cellcycle Progression by KIS in Leukemia Cells.
Authors: Satoki Nakamura, Takaaki Ono, Yuya Sugimoto, Miki Kobayashi, Naohi Sahara, Kaori Shinjo, Kazuyuki Shigeno, Kazunori Ohnishi
Journal: Blood (2005)
Abstract P1-11-13: Re-excision rate in breast conservation surgery after neoadjuvant chemotherapy
Authors: JH Song, JY Park, JE Choi, YK Bae, SJ Lee
Journal: Cancer Research (2017)

Abstract Background : The goal of neoadjuvant chemotherapy is to reduce tumor size and convert mastectomy to breast-conservation surgery (BCS). In response to neoadjuvant chemotherapy, the regression rate and pattern of breast cancer is variable. And the re-excision rate to secure negative resection margin is reported limitedly in this case. The purpose of this study was to compare the re-excision rate and BCS success rate of patients who received and who did not received neoadjuvant chemotherapy. Method : In this retrospective cohort study, between January 2009 and December 2012, total 256 women were included who had clinical T2 breast cancer and were planed to receive BCS as initial operation or neoadjuvant chemotherapy. Fifty-nine patients of them received neoadjuvant chemotherapy. Clinical data were collected including age, preoperative or initial clinical tumor size, mammographic microcalcifications, ultrasound multifocality and axillary nodal status, retrospectively. In the resected specimen from BCS, we reviewed the pathologic tumor size, multifocality, histologic type, hormone receptor and Her-2-neu status, ki67, DCIS and EIC component. The re-excision rate and BCS success rate were investigated. Univariate analysis and regression model were used for identify clinicopathologic factors associated with re-excision. To reduce the effect of selection bias, propensity score matching-based anaylsis was also performed. Results : Of the 256 patients, 178 patients (90.4%, 178/197) received BCS finally in neoadjuvant group and 56 patients (94.9%, 56/59) in non-neoadjuvant group (p=0.406). There was no statistical difference in the re-excision rate between two groups (35.6% (21/59) in neoadjuvant group vs 34.0% (67/197) in non-neoadjuvant group, p=0.946). In propensity-matched cohorts (N=118), the re-excision rate was same in two groups (35.6% (21/59) in neoadjuvant group vs 35.6% (21/59) in non-neoadjuvant group, p=1.000). BCS success rate was higher in neoadjuvant group(94.9% 56/59) than non-neoadjuvant group (86.4%(51/59)), but there was no statistical difference (p=0.205). In this cohorts, clinicopathologic factors associated with re-excision were pathologic multifocality (OR=4.56, p=0.0142), high ki67 (≥50%) (OR=0.7, p=0.0243) and DCIS component (OR=2.67, p=0.0261) in logistic regression model. Conclusion: This study showed neoadjuvant chemotherapy could increase the BCS success rate but could not decrease the re-excision rate. The re-excision rate is more associated with pathologic finding rather than effect of neoadjuvant chemotherapy. Citation Format: Song JH, Park JY, Choi JE, Bae YK, Lee SJ. Re-excision rate in breast conservation surgery after neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-11-13.
Abstract IA06: Patient-derived orthotopic xenografts (PDOX): Better mimic the patient than subcutaneous xenografts
Authors: Robert M. Hoffman
Journal: Clinical Cancer Research (2016)

Abstract The majority of human solid tumors do not metastasize when grown subcutaneously in immunocompromised mice; this includes patient-derived xenograft (PDX) models. However, orthotopic implantation of intact tumor tissue can lead to primary tumor growth and metastasis that mimics that seen in patients. These patient-derived orthotopic xenograft (PDOX) models have a long history and better recapitulate human cancer than PDX models. Citation Format: Robert M. Hoffman. Patient-derived orthotopic xenografts (PDOX): Better mimic the patient than subcutaneous xenografts. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA06.
Geriatric oncology: The ultimate personalized cancer care
Authors: Martine Extermann
Journal: Journal of Clinical Oncology (2009)

s2a In many aspects, geriatric oncology is the quintessential expression of ASCO's 2009 theme: personalizing cancer care (PCC). PCC has two aspects: the tumor and the patient. Major efforts are conducted to identify mechanisms in an individual tumor that could be targeted more effectively by therapies. This research generates huge amounts of data, which creates a challenge in selecting the best therapeutic targets. As senescence has aspects that both prevent and favor cancer, we could take advantage of basic aging research to identify more effectively which mechanisms are key, and which are epiphenomena. Increasingly recognized also is the role of the microenvironment and macroenvironment—the patient—in influencing cancer prognosis and treatment tolerance. Here again, we can learn much from older patients. Seventy-five-year-olds are much more diverse than 25-year-olds. This provides higher sensitivity to detect patient-related factors. The last decade of work in geriatric oncology has demonstrated that geriatric instruments improve prognostic assessment beyond classic oncology predictors. Tantalizing data show that a geriatric intervention might even improve significantly the survival of patients with cancer. We now have screening tools simple enough to be used in oncology practice. In the same way that we are moving away from, for example, lumping all non-small cell lung cancers together, we are moving away from considering the patient condition as a relatively neutral background summarized by an ECOG Performance Status. Older patients also have remarkably diverse life experiences and patterns of functioning. This has enabled significant learning about individualizing the prediction of treatment tolerance and of willingness to undertake it. Geriatric oncology is an ideal terrain to explore end points such as the maintenance of independence and personal goals by cancer survivors. As the world population ages, we are progressing toward providing cancer care tailored to both the tumor and the older cancer patient.
A New Approach to Expand Cord Blood Derived Hematopoietic Stem Cells, Using Bioengineered Human Fetal Liver Tissue 3D-Constructs
Authors: Saloomeh Mokhtari, Pedro Baptista, Dipen Vyas, Charles Jordan Freeman, Emma Moran, Christopher D Porada, Shay Soker, Graca Almeida-Porada
Journal: Blood (2015)
Abstract P2-05-33: Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer
Authors: X Feng, H Li, E Kornarga, M Dean, S Lees-Miller, K Riabowol, A Magliocco, D Morris, P Watson, E Enwere, G Bebb, A Paterson
Journal: Cancer Research (2017)

Abstract Purpose: The current study was designed to investigate the combined influence of ataxia telangiectasia mutated (ATM) and Ki67 on clinical outcome in early stage hormone receptor positive breast cancer (ES-HPBC), particularly in patients with smaller tumors (&amp;lt; 4 cm) and fewer than four positive lymph nodes. Methods: Formalin-fixed paraffin-embedded specimens of resected primary breast tumors from 532 patients diagnosed with early stage breast cancer were used to construct a tissue microarray. Samples from 297 patients were suitable for final statistical analysis. We detected ATM and Ki67 proteins using immunohistochemistry and quantified their expression with digital image analysis. Data on expression levels were subsequently correlated with clinical outcome. Results: Remarkably, ATM expression was useful to stratify the low Ki67 group into subgroups with better or poorer prognosis. Specifically, in the low Ki67 subgroup defined as having smaller tumors and no positive nodes, patients with high ATM expression showed better outcome than those with low ATM, with estimated survival rates of 96% and 89% respectively at 15 years follow up (p = 0.04). Similarly, low-Ki67 patients with smaller tumors, 1-3 positive nodes and high ATM also had significantly better outcomes than their low ATM counterparts, with estimated survival rates of 88% and 46% respectively (p=0.03) at 15 years follow up. Multivariable analysis indicated that the combination of high ATM and low Ki67 is prognostic of improved survival, independent of tumor size, grade, and lymph node status (p = 0.02). Low Ki67/high ATM expression independently predicts favorable disease survival in a multivariate model in low Ki67 subgroup of ES-HPBC (Stage I-III)Variablesp valueHR (95%CI)Low Ki67/high ATM vs Low Ki67/low ATM0.020.36 (0.15-0.88)ize (T1/2 vs T3/4)0.010.16 (0.04-0.69)LN status (- vs +)0.140.49 (0.20-1.25)LVI (_- vs +)0.160.51 (0.20-1.31)Grade (1/2 vs 3)&amp;lt;0.00010.28 (0.11-0.67)Age (&amp;lt;65 vs &amp;gt;65)0.010.26 (0.10-0.74) Conclusions: These data suggest that the prognostic value of Ki67 can be improved by analyzing ATM expression in ES-HPBC. Citation Format: Feng X, Li H, Kornarga E, Dean M, Lees-Miller S, Riabowol K, Magliocco A, Morris D, Watson P, Enwere E, Bebb G, Paterson A. Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-33.
Association of Depression and Cardiovascular Disease
Authors: Roy C. Ziegelstein
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Coronary heart disease.
Authors: J McMurray, H J Dargie
Journal: BMJ (1991)

LI may outweigh the risks of its possible toxicity, and its introduction in such patients may now be appropriate" seem overenthusiastic.Certainly it is in stark contrast to an earlier editorial in the Lancet, which questioned the efficacy of LI and drew attention to the unacceptable incidence of side effects, recommending that "this compound should no longer be given to patients."4
Evaluation of a Novel Thermal Accelerant for Augmentation of Microwave Energy during Image-guided Tumor Ablation
Authors: William Keun Chan Park, Aaron Wilhelm Palmer Maxwell, Victoria Elizabeth Frank, Michael Patrick Primmer, Scott Andrew Collins, Grayson Luderman Baird, Damian Edward Dupuy
Journal: Theranostics (2017)

The primary challenge in thermal ablation of liver tumors (e.g. hepatocellular carcinoma and hepatic colorectal cancer) is the relatively high recurrence rate (~30%) for which incomplete ablation at the periphery of the tumor is the most common reason. In an attempt to overcome this, we have developed a novel thermal accelerant (TA) agent capable of augmenting microwave energy from a distance normally unattainable by a single microwave ablation antenna. This cesium-based block co-polymer compound transforms from a liquid to a gel at body temperature and is intrinsically visible by computed tomography. Using an agarose phantom model, herein we demonstrate that both the rate and magnitude of temperature increase during microwave ablation were significantly greater in the presence of TA when compared with controls. These results suggest robust augmentation of microwave energy, and may translate into larger ablation zone volumes within biologic tissues. Further work using in vivo techniques is necessary to confirm these findings.
Abstract IA02: Introduction to the EuroPDX Consortium
Authors: Sergio Roman-Roman
Journal: Clinical Cancer Research (2016)

Abstract Started in early 2013, EurOPDX gathers 16 academic institutions throughout Europe including 6 Comprehensive Cancer Centres. Each institution is part of a hospital or is collaborating with a neighboring one. EurOPDX includes world-renowned experts at the forefront of research in basic, preclinical, translational and clinical oncology across multiple pathologies, and displays a wide range of expertise in technological platforms. The virtual PDX collection of the consortium consists of more than 1,500 subcutaneous and orthotopic models for more of 30 different pathologies. Our objective is to improve the predictability of preclinical data by (i) improving characterization of the models, (ii) implementing new PDX models to strengthen the representativeness of the collection, and humanized PDX models, (iii) harmonizing working practice, (iv) Integrating complementary models (e.g. ex vivo 2D and 3D assays) in innovative drug development pipelines, and (v) leveraging deep molecular and pharmacogenomic profiling data of the collection of models to discover predictive biomarkers, new targets, and new strategies to overcome drug resistance. In this lecture I will illustrate the value of the consortium with a few examples of collaborative projects involving academic labs but also industrial partners. In particular, I will discuss the current strategies to setting-up the logistics for the performance of multicenter (and sometimes multipathologies) preclinical and co-clinical trials in a collection of fully characterized PDX models. Citation Format: Sergio Roman-Roman. Introduction to the EuroPDX Consortium. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA02.
Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C Patients: A Case-Control Study
Authors: Rafael Simö
Journal: Diabetes Care (2006)

We thank Petit et al. (1) for their interest in our study, in which we suggest that insulin resistance mediated by proinflammatory cytokines, but not a deficit of insulin secretion, is the primary pathogenic mechanism implicated in the development of diabetes associated with hepatitis C virus (HCV) infection (2). Based on the results of our study, these authors measured tumor necrosis factor (TNF)-soluble receptors (TNF-RI and TNF-RII) and homeostasis model assessment (HOMA) in 68 noncirrhotic subjects with chronic …
Reevaluating the Efficacy and Predictability of Antidepressant Treatments
Authors: Adam M. Chekroud, Ralitza Gueorguieva, Harlan M. Krumholz, Madhukar H. Trivedi, John H. Krystal, Gregory McCarthy
Journal: JAMA Psychiatry (2017)

Depressive severity is typically measured according to total scores on questionnaires that include a diverse range of symptoms despite convincing evidence that depression is not a unitary construct. When evaluated according to aggregate measurements, treatment efficacy is generally modest and differences in efficacy between antidepressant therapies are small.To determine the efficacy of antidepressant treatments on empirically defined groups of symptoms and examine the replicability of these groups.Patient-reported data on patients with depression from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (n = 4039) were used to identify clusters of symptoms in a depressive symptom checklist. The findings were then replicated using the Combining Medications to Enhance Depression Outcomes (CO-MED) trial (n = 640). Mixed-effects regression analysis was then performed to determine whether observed symptom clusters have differential response trajectories using intent-to-treat data from both trials (n = 4706) along with 7 additional placebo and active-comparator phase 3 trials of duloxetine (n = 2515). Finally, outcomes for each cluster were estimated separately using machine-learning approaches. The study was conducted from October 28, 2014, to May 19, 2016.Twelve items from the self-reported Quick Inventory of Depressive Symptomatology (QIDS-SR) scale and 14 items from the clinician-rated Hamilton Depression (HAM-D) rating scale. Higher scores on the measures indicate greater severity of the symptoms.Of the 4706 patients included in the first analysis, 1722 (36.6%) were male; mean (SD) age was 41.2 (13.3) years. Of the 2515 patients included in the second analysis, 855 (34.0%) were male; mean age was 42.65 (12.17) years. Three symptom clusters in the QIDS-SR scale were identified at baseline in STAR*D. This 3-cluster solution was replicated in CO-MED and was similar for the HAM-D scale. Antidepressants in general (8 of 9 treatments) were more effective for core emotional symptoms than for sleep or atypical symptoms. Differences in efficacy between drugs were often greater than the difference in efficacy between treatments and placebo. For example, high-dose duloxetine outperformed escitalopram in treating core emotional symptoms (effect size, 2.3 HAM-D points during 8 weeks, 95% CI, 1.6 to 3.1; P < .001), but escitalopram was not significantly different from placebo (effect size, 0.03 HAM-D points; 95% CI, -0.7 to 0.8; P = .94).Two common checklists used to measure depressive severity can produce statistically reliable clusters of symptoms. These clusters differ in their responsiveness to treatment both within and across different antidepressant medications. Selecting the best drug for a given cluster may have a bigger benefit than that gained by use of an active compound vs a placebo.
Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN
Authors: Alex F Herrera, Allison Crosby-Thompson, Jonathan W. Friedberg, Gregory A. Abel, Myron S. Czuczman, Leo I. Gordon, Mark S. Kaminski, Michael Millenson, Auayporn Nademanee, Joyce Niland, Maria A. Rodriguez, Andrew D. Zelenetz, Ann S. LaCasce
Journal: Blood (2012)
The Evolutionary Dynamics of Orthologs That Shift in Gene Body Methylation between Arabidopsis Species
Authors: Shohei Takuno, Danelle K. Seymour, Brandon S. Gaut
Journal: Molecular Biology and Evolution (2017)

DNA methylation labels a specific subset of genes in plant genomes. Recent work has shown that this gene-body methylation (gbM) is a conserved feature of orthologs, because highly methylated genes in one species tend to be highly methylated in another. In this study, we examined the exceptions to that rule by identifying genes that differ in gbM status between two plant species—Arabidopsis thaliana and Arabidopsis lyrata. Using Capsella grandiflora as an outgroup, we polarized the loss and gain of gbM for orthologs in the Arabidopsis lineage. Our survey identified a few hundred genes that differed between ingroup species, out of ∼9,000 orthologs. The estimated rate of gbM gain was ∼2 × 10−9 per gene per year for both ingroup taxa and was similar to the loss rate in A. lyrata. In contrast, A. thaliana had a ∼3-fold higher estimated rate of gbM loss per gene, consistent with a recent diminishment of genome size. As in previous studies, we found that body-methylated genes were expressed broadly across tissues and were also longer than other genic sets. Genes that differed in gbM status exhibited higher variance in expression between species than genes that were body-methylated in both species. Moreover, the gain of gbM in one lineage tended to be associated with an increase of expression in that lineage. The genes that varied in gbM status between species varied more significantly in length between species than other sets of genes; we hypothesize that length is a key feature in the transition between body-methylated and nonmethylated genes.
Follicular Dendritic Cell (FDC)-Induced Microrna-Mediated up-Regulation of PRDM1 and Down-Regulation of BCL6 in Germinal Center B Lymphocytes: A Potential Mechanism for B-Cell Differentiation.
Authors: Jianhong Lin, Tint Lwin, Jianjun Zhao, Jie Zhao, Luis Crespo, Eduardo M. Sotomayor, Lynn C. Moscinski, William S. Dalton, Ken Wright, Jianguo Tao
Journal: Blood (2009)
Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial
Authors: Francisco Javier Peñalver Párraga, José Antonio Márquez Navarro, Soledad Durán Nieto, Pilar Giraldo Castellano, Carlos Montalbán Sanz, María José Ramírez Sánchez, Juan-Manuel Sancho Cia, María José Terol Castera, Francisco Javier Capote Huelva, Antonio Gutiérrez García, Blanca Sánchez González, Antonio Salar Silvestre, Miguel Canales Albendea, María Dolores Caballero Barrigón
Journal: Blood (2016)
Design and Synthesis of Novel Derivatives of ATRA Demonstrate the Combined Importance of Acid Moiety and Conjugated Double Bonds in Its Binding to PMLRAR-Alpha Oncogene in Acute Promyelocytic Leukemia
Authors: Swati Goel, Carolina Schinke, Tushar Bhagat, Yongkai Mo, Li Zhou, Christoph Heuck, Christina Alencar, Perry Pahanish, Jaime Anguiano, George Kabalka, Leonidas C Platanias, Amit Verma, Bhaskar Das
Journal: Blood (2008)
Evolution of a True B-Cell Chronic Lymphocytic Leukaemia (B-CLL) in a Diffuse Immunocytoma after Treatment with Fludarabine.
Authors: Paolo Bernasconi, Marco Paulli, Ester Orlandi, Vittorio Perfetti, Ilaria Giardini, Silvia Zibellini, Laura Vanelli, Annamaria Tenore, Marina Boni, Paola Maria Cavigliano, Alessandra Algarotti, Ercole Brusamolino, Mario Lazzarino
Journal: Blood (2005)
Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites
Authors: Tao Long, Michael Hicks, Hung-Chun Yu, William H Biggs, Ewen F Kirkness, Cristina Menni, Jonas Zierer, Kerrin S Small, Massimo Mangino, Helen Messier, Suzanne Brewerton, Yaron Turpaz, Brad A Perkins, Anne M Evans, Luke A D Miller, Lining Guo, C Thomas Caskey, Nicholas J Schork, Chad Garner, Tim D Spector, J Craig Venter, Amalio Telenti
Journal: Nature Genetics (2017)
Abstract P5-15-18: MERIBEL STUDY: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)
Authors: V Ortega, A Antón, I Garau, N Afonso, L Calvo, Y Fernández, M Martinez-Garcia, E Blanco, P Zamora, M García, JJ Illarramendi, CA Rodríguez, E Aguirre, J Pérez, J Cortés, A Llombart
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.